These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30614347)

  • 41. Testosterone replacement therapy and prostate cancer.
    Morgentaler A
    Urol Clin North Am; 2007 Nov; 34(4):555-63, vii. PubMed ID: 17983895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Testosterone replacement therapy and prostate cancer: the downfall of a paradigm?].
    Castillo OA; López-Fontana G; Vidal-Mora I; López Laur JD
    Medwave; 2015 Apr; 15(3):e6115. PubMed ID: 25919660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Testosterone replacement therapy improves health-related quality of life for patients with late-onset hypogonadism: a meta-analysis of randomized controlled trials.
    Nian Y; Ding M; Hu S; He H; Cheng S; Yi L; Li Y; Wang Y
    Andrologia; 2017 May; 49(4):. PubMed ID: 27389320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
    Yassin AA; Nettleship JE; Salman M; Almehmadi Y
    Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
    Klap J; Schmid M; Loughlin KR
    J Urol; 2015 Feb; 193(2):403-13. PubMed ID: 25260832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of androgen secretion disorders in men with a malignancy.
    Wiechno PJ; Poniatowska GM; Michalski W; Kucharz J; Sadowska M; Jonska-Gmyrek J; Nietupski K; Rzymowska J; Demkow T
    Med Oncol; 2017 Jul; 34(7):123. PubMed ID: 28573637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review of Testim gel.
    McNicholas T; Ong T
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
    Heaton JP
    Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermittent androgen suppression in prostate cancer: testosterone levels and its implication.
    Mearini L; Zucchi A; Costantini E; Bini V; Porena M
    J Sex Med; 2011 Apr; 8(4):1218-27. PubMed ID: 21235718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Basis for hormonal management of advanced prostate cancer.
    Geller J
    Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.
    Shabsigh R; Crawford ED; Nehra A; Slawin KM
    Int J Impot Res; 2009; 21(1):9-23. PubMed ID: 18633357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial.
    Ng Tang Fui M; Hoermann R; Prendergast LA; Zajac JD; Grossmann M
    Int J Obes (Lond); 2017 Mar; 41(3):420-426. PubMed ID: 28028318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer.
    Catarinicchia SP; Crawford ED
    Nat Rev Urol; 2016 Sep; 13(9):497-8. PubMed ID: 27431338
    [No Abstract]   [Full Text] [Related]  

  • 58. Androgen replacement in men undergoing treatment for prostate cancer.
    Rhoden EL; Averbeck MA; Teloken PE
    J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgens and prostate cancer risk: a prospective study.
    Wirén S; Stocks T; Rinaldi S; Hallmans G; Bergh A; Stenman UH; Kaaks R; Stattin P
    Prostate; 2007 Aug; 67(11):1230-7. PubMed ID: 17562541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgens and prostate cancer; pathogenesis and deprivation therapy.
    Grossmann M; Cheung AS; Zajac JD
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.